- Home
- TRAW vs CYCC Comparison
TRAW vs CYCC Comparison
Compare TRAW & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRAW
- CYCC
- Stock Information
- Founded
- TRAW 1998
- CYCC 1992
- Country
- TRAW United States
- CYCC Malaysia
- Employees
- TRAW N/A
- CYCC 12
- Industry
- TRAW
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- TRAW
- CYCC Health Care
- Exchange
- TRAW NYSE
- CYCC Nasdaq
- Market Cap
- TRAW 8.6M
- CYCC 8.3M
- IPO Year
- TRAW 2013
- CYCC N/A
- Fundamental
- Price
- TRAW $1.48
- CYCC $0.34
- Analyst Decision
- TRAW
- CYCC
- Analyst Count
- TRAW 0
- CYCC 0
- Target Price
- TRAW N/A
- CYCC N/A
- AVG Volume (30 Days)
- TRAW 3.4M
- CYCC 3.9M
- Earning Date
- TRAW 08-14-2025
- CYCC 08-13-2025
- Dividend Yield
- TRAW N/A
- CYCC N/A
- EPS Growth
- TRAW N/A
- CYCC N/A
- EPS
- TRAW N/A
- CYCC N/A
- Revenue
- TRAW $227,000.00
- CYCC $14,000.00
- Revenue This Year
- TRAW $3.81
- CYCC $137.21
- Revenue Next Year
- TRAW $30.43
- CYCC N/A
- P/E Ratio
- TRAW N/A
- CYCC N/A
- Revenue Growth
- TRAW 0.44
- CYCC N/A
- 52 Week Low
- TRAW $0.97
- CYCC $0.25
- 52 Week High
- TRAW $19.44
- CYCC $39.84
- Technical
- Relative Strength Index (RSI)
- TRAW 43.63
- CYCC 26.19
- Support Level
- TRAW $1.37
- CYCC $0.31
- Resistance Level
- TRAW $1.49
- CYCC $0.41
- Average True Range (ATR)
- TRAW 0.11
- CYCC 0.06
- MACD
- TRAW -0.03
- CYCC 0.10
- Stochastic Oscillator
- TRAW 12.07
- CYCC 34.89
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.